We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A closer look at reported colitis in association with multiple sclerosis treatments.
- Authors
Porwal, Mokshal H; Obeidat, Ahmed Z
- Abstract
A recent article in the Multiple Sclerosis Journal discussed a case series of 38 patients who developed immune colitis while receiving ocrelizumab for multiple sclerosis (MS) treatment. The US Food and Drug Administration (FDA) prescribing label was updated to reflect the potential risk for immune colitis in people with MS receiving ocrelizumab. However, the FDA Adverse Event Reporting System (FAERS) has limitations, and it is unclear if immune colitis is associated with the specific drug or with MS itself. An analysis of data from 13 different MS treatments found that ocrelizumab had a higher reporting odds ratio (ROR) for colitis compared to other drugs. Further research is needed to understand the mechanism, incidence, and risk mitigation strategies associated with ocrelizumab and colitis.
- Subjects
MULTIPLE sclerosis; COLITIS; INTERFERON beta 1b; INFLAMMATORY bowel diseases; MEDICAL personnel; AUTOIMMUNE diseases; ISCHEMIC colitis
- Publication
Multiple Sclerosis Journal, 2024, Vol 30, Issue 3, p453
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/13524585231205964